Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.
Hoshijima
Masahiko
M
Center for Research in Biological Systems, the Department of Medicine, National Center for Microscopy and Imaging Research, University of California-San Diego, La Jolla, CA, USA. mhoshijima@ucsd.edu
Hayashi
Takeharu
T
Jeon
Young E
YE
Fu
Zhenxing
Z
Gu
Yusu
Y
Dalton
Nancy D
ND
Ellisman
Mark H
MH
Xiao
Xiao
X
Powell
Frank L
FL
Ross
John
J
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D018450:Disease Progression; D015316:Genetic Therapy; D006333:Heart Failure / Q000235:genetics / Q000517:prevention & control*; D008136:Longevity / Q000235:genetics; D008297:Male; D008647:Mesocricetus; D009135:Muscular Diseases / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D012131:Respiratory Insufficiency / Q000235:genetics / Q000517:prevention & control*; D012132:Respiratory Muscles / Q000473:pathology; D049031:Sarcoglycans / Q000235:genetics / Q000627:therapeutic use*
D002317:Cardiovascular Agents; D049031:Sarcoglycans